Since 1995, Reliable Business Intelligence for Clinical Laboratories, Pathology Groups and Laboratory Diagnostics

Subscriber?

Volume XX No. 3 - March 4, 2013

Leveraging Testing Technology To Identify MRSA, C. Difficile

Clinical Laboratory / By

CEO SUMMARY: Probably the most challenging infections for hospitals to control and reduce are methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C. diff). The laboratory at one New York hospital introduced algorithms to screen for the presence of each infection. In the past five years, the hospital not only cut costs by almost $3 million …

Leveraging Testing Technology To Identify MRSA, C. Difficile Read More »

To access this post, you must purchase The Dark Report.

Predicting the End of Fee-for-Service Medicine

Commentary and Opinion by R. Lewis Dark / By

HOW DISRUPTIVE WILL THE END OF FEE-FOR-SERVICE MEDICINE be to the lab testing industry? I ask this question because we are about to leave the era of fee-for-service (FFS) medicine and move into the era of value-based and bundled reimbursement. Since World War II, FFS has been the overwhelmingly dominant payment model for the healthcare …

Predicting the End of Fee-for-Service Medicine Read More »

To access this post, you must purchase The Dark Report.

Urologists Weigh in on Prostate Biopsy Testing

Anatomic Pathology / By

CEO SUMMARY: Based on an impressive number of 4,230,129 vials collected from 437,937 biopsies, the new study is expected to add fuel to the fire of the ongoing debate about the appropriate number of prostate biopsies physicians should collect and refer to pathology labs for cancer testing. The researchers compared the number of prostate biopsies …

Urologists Weigh in on Prostate Biopsy Testing Read More »

To access this post, you must purchase The Dark Report.

Palmetto’s Prostate Biopsy Policy Removed after Talks with CMS

Clinical Laboratory / By

THERE IS SOME POSITIVE LAB INDUSTRY NEWS that has not been widely reported yet. It involves a decision to change an unwelcome Medicare policy that limited the number of prostate biopsy specimens per case that would be reimbursed. After discussions between lab industry groups and the federal Centers for Medicare & Medicaid Services (CMS), Palmetto …

Palmetto’s Prostate Biopsy Policy Removed after Talks with CMS Read More »

To access this post, you must purchase The Dark Report.

Two MTs Launch New Lab In Aberdeen, North Carolina

Clinical Laboratory / By

CEO SUMMARY: Although located in the same region as two of the nation’s largest laboratory companies, newly-created Triune Laboratory, Inc., is reporting steady growth and acceptance by physicians in the community. Founded by two medical technologists and partially funded by a pathologist, this new lab company demonstrates that many physicians are ready to support an …

Two MTs Launch New Lab In Aberdeen, North Carolina Read More »

To access this post, you must purchase The Dark Report.

LipoScience Completes IPO, Raises $44.9 Million from Sale

Clinical Laboratory / By

IT HAS BEEN A WHILE since a laboratory company has successfully completed an initial public offering (IPO). Thus, it is notable that LipoScience Inc., of Raleigh, North Carolina, recently accomplished that feat. On January 24, 2013, Liposcience closed its IPO and raised $44.9 million. It now trades on NASDAQ under the stock symbol LPDX. The …

LipoScience Completes IPO, Raises $44.9 Million from Sale Read More »

To access this post, you must purchase The Dark Report.

EHR Donation Ruling in WA Raises Questions for Labs

Laboratory Compliance / By

CEO SUMMARY: When the Washington State Attorney General issued an Attorney General Opinion last fall, he created confusion among pathologists and lab directors whose labs have paid to have EHR software installed in physicians’ offices. The Washington AG’s ruling not only conflicts with federal law, which allows labs to donate EHR software, but raises questions …

EHR Donation Ruling in WA Raises Questions for Labs Read More »

To access this post, you must purchase The Dark Report.

March 4, 2013 “Intelligence: Late-Breaking Lab News”

Late Breaking Lab News / By

Even if not billion-dollar transactions, there are some interesting deals unfolding in the in vitro diagnostics (IVD) marketplace. Last month, HYCOR Biomedical, Inc., of Garden Grove, California, sold its Kova urinalysis system and business “to an affiliate of One Rock Capital Partners, Laurel Crown Partners, and StoneCreek Capital,” according to a Hycor press release. As …

March 4, 2013 “Intelligence: Late-Breaking Lab News” Read More »

To access this post, you must purchase The Dark Report.

Facebook-f Twitter Linkedin-in

The Dark Report • 21806 Briarcliff Dr • Spicewood, TX 78669
Phone: 512-264-7103 • Toll Free Number: 800-560-6363
Email: info@darkreport.com

© 2024 The Dark Report. All rights reserved.

;